AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new ROMEO study tracks how safe its COPD drug tozoraki...

AstraZeneca Extends COPD Bet With New Long‑Term Tozorakimab Safety Study

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a first-in-human trial named “Phase I/II Dose...

AstraZeneca Advances First-in-Human AZD8359 Study in Metastatic Prostate Cancer

Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed ...

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

An update from AstraZeneca ( ($GB:AZN) ) is now available. AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval for two new indications of...

FDA approvals extend Enhertu into curative-intent HER2-positive early breast cancer

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new SECURE study, officially titled “Cross-sectional Q...

AstraZeneca’s SECURE Study Targets Real-World Tagrisso Persistence in China

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a chart review study in China called “A Multi...

AstraZeneca Deepens China Lung Cancer Insights With New NSCLC Chart Review

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The PREDICT study, officially titled “A Prospective, Multicenter Rea...

AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a new real‑world study called “Effectiveness ...

AstraZeneca Expands Real‑World Evidence for Anifrolumab in Lupus Care

In a report released today, Emmanuel Papadakis from Deutsche Bank reiterated a Sell rating on AstraZeneca, with a price target of p11,500.00. Accor...

Deutsche Bank  Reaffirms Their Sell Rating on AstraZeneca (AZN)

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new liver function trial could shape future dosing rul...

AstraZeneca Advances Early Liver-Function Trial That Could Shape Dosing for Future AZN Drugs

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca today and set a price target of £186.00. According to TipRanks, Smith is a 4-...

Bernstein Remains a Buy on AstraZeneca (AZN)

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The CICERO study, officially titled “A Non-interventional, Prospective, Op...

AstraZeneca’s Calquence Gets Real World Safety Check in CLL Patients on Blood Thinners

AstraZeneca ( ($GB:AZN) ) has shared an update. AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing, ...

AstraZeneca Updates Total Voting Rights and Admits New Shares from Employee Schemes

In a report released yesterday, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca. The company’s shares closed yesterday at p13,948....

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

Citi analyst Graham Parry maintained a Buy rating on AstraZeneca yesterday. The company’s shares closed yesterday at p13,948.00. According to TipRa...

Citi Remains a Buy on AstraZeneca (AZN)

Kepler Capital analyst David Evans maintained a Hold rating on AstraZeneca on April 29 and set a price target of p11,300.00. The company’s shares c...

Kepler Capital  Reaffirms Their Hold Rating on AstraZeneca (AZN)

J.P. Morgan analyst Richard Vosser maintained a Buy rating on AstraZeneca today and set a price target of £160.00. According to TipRanks, Vosser is...

J.P. Morgan Remains a Buy on AstraZeneca (AZN)

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca today and set a price target of p17,600.00. According to TipRanks, Weston is a 4-...

UBS Remains a Buy on AstraZeneca (AZN)

Deutsche Bank analyst Emmanuel Papadakis reiterated a Sell rating on AstraZeneca today and set a price target of p11,500.00. Papadakis covers the H...

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AZN	$187.33	+0.16%	917.09K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AZN	$187.33	+0.2%	917.09K
3
4
5
6

AZN

AZN

Get AstraZeneca PLC Data in Excel

Get AstraZeneca PLC Data in Excel